Antares Pharma, Inc. (ATRS) News

Antares Pharma, Inc. (ATRS): $5.59

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ATRS News Items

ATRS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ATRS News Highlights

  • For ATRS, its 30 day story count is now at 5.
  • Over the past 21 days, the trend for ATRS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ATRS are DRUG, HSIC and LI.

Latest ATRS News From Around the Web

Below are the latest news stories about Antares Pharma Inc that investors may wish to consider to help them evaluate ATRS as an investment opportunity.

Antares Pharma (NASDAQ:ATRS) Could Easily Take On More Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Yahoo | February 18, 2022

Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results

EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens. Antares will host a conference call on Thursday, March 3, 2022 at 8:30am ET to discuss the results. The dial-in numbers are (888) 254-3590 for domestic callers and (323) 794-2551 for international callers. The

Yahoo | February 17, 2022

Henry Schein (HSIC) Q4 Earnings and Revenues Beat Estimates

Henry Schein (HSIC) delivered earnings and revenue surprises of 18.89% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 15, 2022

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO®

PDUFA target action date set for March 28, 2022EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”) resubmission for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”). The FDA designated the NDA as a Class 1 resubmission with a two-month review goal perio

Yahoo | February 3, 2022

Arrow Financial Corp Buys iShares Core MSCI International Developed Markets , PowerShares QQQ ...

Glens Falls, NY, based Investment company Arrow Financial Corp (Current Portfolio) buys iShares Core MSCI International Developed Markets , PowerShares QQQ Trust Ser 1, Caterpillar Inc, Dollar Tree Inc, Activision Blizzard Inc, sells Netflix Inc, iShares iBonds Dec 2021 Term Corporate ETF, Lockheed Martin Corp, Gilead Sciences Inc, Goldman Sachs Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Arrow Financial Corp.

Yahoo | January 28, 2022

A Look At Recent Moves By Antares Pharma

No summary available.

Seeking Alpha | January 24, 2022

FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity

The FDA has granted Fast Track designation to Antares Pharma Inc''s (NASDAQ: ATRS ) for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using Vai proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone. The

Benzinga | January 18, 2022

Antares Pharma''s ATRS-1902 gets US FDA fast track status for adrenal crisis rescue

Antares Pharma''s (ATRS) hydrocortisone rescue pen ATRS-1902 received the U.S

Seeking Alpha | January 18, 2022

Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue

EWING, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai™ novel proprietary auto-injector pla

Yahoo | January 18, 2022

Antares Pharma, Inc.'s (NASDAQ:ATRS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Most readers would already be aware that Antares Pharma's (NASDAQ:ATRS) stock increased significantly by 11% over the...

Yahoo | January 13, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.532 seconds.